Detailed Abstract
[BP Poster Presentation 2]
[BP PP 2-6] Controversial oncologic benefit of adjuvant therapy for ampullary cancer: A propensity score matched analysis
Byung Chang KIM, Woohyung LEE*, Yejong PARK, Jae Woo KWON, Ki Byung SONG, Jae Hoon LEE, Dae Wook HWANG, Song Cheol KIM
Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, Asan Medical Center, Korea
Introduction : Controversial oncologic benefit of adjuvant therapy for ampullary cancer: A Propensity score matched analysis
Methods : AC patients who underwent pancreaticoduodnectomy were included between 2011 and 2019. Survival and recurrence were compared between observation (OB) and adjuvant chemotherapy (CTx) group after propensity score matching (PSM) using perioperative variables to reduce different patients characteristics between two groups.
Results : Of 476 patients, OB group showed larger tumor size (2.1 vs 1.8 cm, p = 0.002), higher T stage (1,2 vs 3,4; 55.8 vs 19.0 %, p < 0.001), N stage (0 vs 1; 58.3 vs 18.4 %, p < 0.001) using AJCC 7th, poor differentiation (17.5 vs 6.8 %, p < 0.001), lymphovascular invasion (LVI) (83.5 vs 30.1%, p < 0.001), perineural invasion (PNI) (44.3 vs 13.4 %, p < 0.001), and high carbohydrate antigen 19-9 >37 IU/L (42.2 vs 26.7%, p = 0.006) compared with OB group before PSM. Median follow up period was 33.4 months. The 5-year overall survival (OS) (68.8 vs 60.3%, p = 0.005) and recurrence free survival (RFS) rate (71.5 vs 42.2 %, p < 0.001) showed poor prognosis in CTx group compared OB group before PSM. . After PSM, perioperative outcomes were comparable. In oncologic outcomes, the 5-year OS (65.7 vs 62.6%, p = 0.659) and RFS (48.7 vs 56.1 %, p = 0.741) rate was not
Conclusions : The patients with adjuvant chemotherapy showed comparable oncologic outcome compared the patients without adjuvant therapy. Large study will give us confirmative results of role of adjuvant therapy for ampullary cancer.
Methods : AC patients who underwent pancreaticoduodnectomy were included between 2011 and 2019. Survival and recurrence were compared between observation (OB) and adjuvant chemotherapy (CTx) group after propensity score matching (PSM) using perioperative variables to reduce different patients characteristics between two groups.
Results : Of 476 patients, OB group showed larger tumor size (2.1 vs 1.8 cm, p = 0.002), higher T stage (1,2 vs 3,4; 55.8 vs 19.0 %, p < 0.001), N stage (0 vs 1; 58.3 vs 18.4 %, p < 0.001) using AJCC 7th, poor differentiation (17.5 vs 6.8 %, p < 0.001), lymphovascular invasion (LVI) (83.5 vs 30.1%, p < 0.001), perineural invasion (PNI) (44.3 vs 13.4 %, p < 0.001), and high carbohydrate antigen 19-9 >37 IU/L (42.2 vs 26.7%, p = 0.006) compared with OB group before PSM. Median follow up period was 33.4 months. The 5-year overall survival (OS) (68.8 vs 60.3%, p = 0.005) and recurrence free survival (RFS) rate (71.5 vs 42.2 %, p < 0.001) showed poor prognosis in CTx group compared OB group before PSM. . After PSM, perioperative outcomes were comparable. In oncologic outcomes, the 5-year OS (65.7 vs 62.6%, p = 0.659) and RFS (48.7 vs 56.1 %, p = 0.741) rate was not
Conclusions : The patients with adjuvant chemotherapy showed comparable oncologic outcome compared the patients without adjuvant therapy. Large study will give us confirmative results of role of adjuvant therapy for ampullary cancer.
SESSION
BP Poster Presentation 2
E-Session 7/27 ~ 7/29 ALL DAY